Beneficial effects on cardiovascular death or hospitalisation for heart failure were consistent in the CKD trials with the totality of evidence across all SGLT-2 inhibitor trials, including those in heart failure-specific populations [4]. The gene discussed is SLC5A2; the disease is chronic kidney disease.